Cellares, an integrated development and manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, reported that Bristol Myers Squibb has joined its Technology Adoption Partnership (TAP) program. As part of the agreement, BMS will enter into a proof-of-concept transfer process for the manufacture of one of its CAR-T cell therapies using Cellares’ automated manufacturing platform, the Cell Shuttle. Cellares’ TAP program allows cell therapy develope...